GlassScriptPhysician profile
Melanie Nuss
NPI 1710916978
$4,508.87
in general payments reported to CMS, 2019-2025
23 companies · $664 in 2025
The $664 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,117 · 2022: $898 · 2023: $744 · 2024: $1,086 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,379 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,379.23 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $832.36 | 2021-2025 | |
| Pfizer INC. | $494.30 | 2021-2025 | |
| Ucb, INC. | $452.35 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $417.27 | 2021-2025 | Tremfya |
| Allergan, INC. | $369.63 | 2021-2022 | |
| Genzyme Corporation | $326.84 | 2021-2024 | |
| Amgen INC. | $312.55 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $204.83 | 2021-2022 | |
| Incyte Corporation | $161.28 | 2022-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $153.23 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $140.93 | 2021-2024 | Libtayo |
| Organogenesis INC. | $117.19 | 2023 | Puraply |
| Novartis Pharmaceuticals Corporation | $110.09 | 2021-2025 | |
| Leo Pharma INC. | $91.87 | 2021-2025 | Adbry, Spevigo |
| Lilly USA, LLC | $90.48 | 2023-2025 | Ebglyss, Taltz, Olumiant |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $54.05 | 2022-2023 | Sotyktu |
| Medimetriks Pharmaceuticals, INC. | $44.92 | 2021-2025 | Neo-Synalar |
| Arcutis Biotherapeutics, INC. | $40.71 | 2023-2024 | Zoryve |
| Verrica Pharmaceuticals INC. | $29.20 | 2023 | Ycanth |
| Almirall LLC | $21.38 | 2022 | |
| Bioventus LLC | $16.23 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.50 | 2024 | Nuzyra |
| Galderma Laboratories, L.P. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Nuss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.